Changes in the gut microbiota can have a positive or a negative impact on the response to the new anti-PD-1 cancer therapies.
Understanding the factors influencing such response is fundamental.
We discussed it with Giorgio Trinchieri, Head of the Cancer Immunology Section at NIH (USA), who is conducting some research on the impact of faecal microbiota transplantation on immuno-oncology.
The interview was done at MIBIOC – Milan, the first international congress on the relationship between microbiota and cancer.
